Corvus Pharmaceuticals Shares Rise 14% Ahead of Soquelitinib Trial Data Reveal

Dow Jones12-18

By Denny Jacob

Corvus Pharmaceuticals shares rose 14% in after-market trading after the company said it would announce interim data from a Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis.

Shares were trading around $8.40 late Tuesday. For the year, the stock is up 320%.

The clinical-stage biopharmaceutical company said it will announce its data on Wednesday in a press release and present during a conference call and webcast.

Soquelitinib is an investigational treatment that selectively inhibits ITK, an enzyme that is expressed mostly in T cells and plays a role in T cell and natural killer cell immune function, according to Corvus.

Write to Denny Jacob at denny.jacob@wsj.com

(END) Dow Jones Newswires

December 17, 2024 17:53 ET (22:53 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492735911?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-18 06:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492735911","market":"hk","top_or_hot":-1,"title":"Corvus Pharmaceuticals Shares Rise 14% Ahead of Soquelitinib Trial Data Reveal","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Denny Jacob \n</p>\n<pre>\n \n</pre>\n<p>\n  Corvus Pharmaceuticals shares rose 14% in after-market trading after the company said it would announce interim data from a Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis. \n</p>\n<p>\n  Shares were trading around $8.40 late Tuesday. For the year, the stock is up 320%. \n</p>\n<p>\n  The clinical-stage biopharmaceutical company said it will announce its data on Wednesday in a press release and present during a conference call and webcast. \n</p>\n<p>\n  Soquelitinib is an investigational treatment that selectively inhibits ITK, an enzyme that is expressed mostly in T cells and plays a role in T cell and natural killer cell immune function, according to Corvus. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 17, 2024 17:53 ET (22:53 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Corvus Pharmaceuticals Shares Rise 14% Ahead of Soquelitinib Trial Data Reveal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCorvus Pharmaceuticals Shares Rise 14% Ahead of Soquelitinib Trial Data Reveal\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-18 06:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Denny Jacob \n\n\n \n\n\n  Corvus Pharmaceuticals shares rose 14% in after-market trading after the company said it would announce interim data from a Phase 1 clinical trial evaluating soquelitinib in ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4568","symbol_name":"美国抗疫概念","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2492735911","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492735911","pubTimestamp":1734475980,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Corvus Pharmaceuticals shares rose 14% in after-market trading after the company said it would announce interim data from a Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis.Shares were trading around $8.40 late Tuesday. For the year, the stock is up 320%.The clinical-stage biopharmaceutical company said it will announce its data on Wednesday in a press release and present during a conference call and webcast.Soquelitinib is an investigational treatment that selectively inhibits ITK, an enzyme that is expressed mostly in T cells and plays a role in T cell and natural killer cell immune function, according to Corvus.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4568":"美国抗疫概念","BK4139":"生物科技","CRVS":"Corvus Pharmaceuticals, Inc."},"translate_title":"索奎替尼试验数据公布前Corvus Pharmaceuticals股价上涨14%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRVS":1},"content_text":"By Denny Jacob \n\n\n \n\n\n  Corvus Pharmaceuticals shares rose 14% in after-market trading after the company said it would announce interim data from a Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis. \n\n\n  Shares were trading around $8.40 late Tuesday. For the year, the stock is up 320%. \n\n\n  The clinical-stage biopharmaceutical company said it will announce its data on Wednesday in a press release and present during a conference call and webcast. \n\n\n  Soquelitinib is an investigational treatment that selectively inhibits ITK, an enzyme that is expressed mostly in T cells and plays a role in T cell and natural killer cell immune function, according to Corvus. \n\n\n \n\n\n  Write to Denny Jacob at denny.jacob@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 17, 2024 17:53 ET (22:53 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492735911"}